10-Years Follow-up of the EXAMINATION Trial

Conditions

Cardiovascular Diseases, Heart Disease, Infarction, Myocardial Infarction, Necrosis, ST Elevation Myocardial Infarction, Vascular Diseases

Keywords

Acute myocardial infarction, Primary Percutaneous Coronary Intervention, Drug-Eluting Stent

Brief summary

The EXAMINATION trial was a superiority trial that compared everolimus-eluting stents (EES) versus bare-metal stents (BMS) in an all-comer ST-segment elevation myocardial infarction (STEMI) population. The patient-oriented endpoint was not superior at 1-year, but it was at 5-year. However, very-long term follow-up is unknown. The study had an independent Clinical event Committee (CEC). All events were adjudicated by an independent clinical committee, according to the Academic Research Consortium 1.

Vidal-Calés P, Bujak K, Rinaldi R, Salazar-Rodríguez A, Ortega-Paz L, Gómez-Lara J, Jiménez-Díaz V, Jiménez M, Jiménez-Quevedo P, Diletti R, Bordes P, Campo G, Silvestro A, Maristany J, Flores X, Miguel-Castro A, Íñiguez A, Ielasi A, Tespili M, Lenzen M, Gonzalo N, Tebaldi M, Biscaglia S, Romaguera R, Gómez-Hospital JA, Serruys PW, Sabaté M, Brugaletta S.

2025-01-29

10.24875/recic.m24000491

Long-term prognostic impact of the left anterior descending coronary artery as the STEMI-related culprit vessel: subanalysis of the EXAMINATION-EXTEND trial

Pablo Vidal-Calés, Kamil Bujak, Riccardo Rinaldi, Anthony Salazar-Rodríguez, Luis Ortega-Paz et al. (27 authors)

REC interventional cardiology (English Edition)2024-12-161 citations

10.24875/recice.m24000488

Ten-year prognostic impact of target versus non-target vessel failure after STEMI. Insight from the EXAMINATION-EXTEND trial

Filippo Maria Verardi, Kamil Bujak, Paolo Tolomeo, Josep Gómez‐Lara, Víctor Alfonso Jiménez Díaz et al. (27 authors)

Revista Española de Cardiología (English Edition)2023-07-26

10.1016/j.rec.2023.07.001

Impact of Diabetes on 10‐Year Outcomes Following ST‐Segment–Elevation Myocardial Infarction: Insights From the EXAMINATION‐EXTEND Trial

Francesco Spione, Víctor Arévalos, Rami Gabani, Luis Ortega‐Paz, Josep Gómez‐Lara et al. (32 authors)

Journal of the American Heart Association2022-11-293 citations

10.1161/jaha.122.025885

Sex Differences in 10-Year Outcomes Following STEMI: A Subanalysis From the EXAMINATION-EXTEND Trial.

Gabani R, Spione F, Arevalos V, Grima Sopesens N, Ortega-Paz L, Gomez-Lara J, Jimenez-Diaz V, Jimenez M, Jiménez-Quevedo P, Diletti R, Pineda J, Campo G, Silvestro A, Maristany J, Flores X, Oyarzabal L, Bastos-Fernandez G, Iñiguez A, Serra A, Escaned J, Ielasi A, Tespili M, Lenzen M, Gonzalo N, Bordes P, Tebaldi M, Biscaglia S, Al-Shaibani S, Romaguera R, Gomez-Hospital JA, Rodes-Cabau J, Serruys PW, Sabaté M, Brugaletta S.

2022-08-2219 citations

10.1016/j.jcin.2022.07.038

10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.

Brugaletta S, Gomez-Lara J, Ortega-Paz L, Jimenez-Diaz V, Jimenez M, Jiménez-Quevedo P, Diletti R, Mainar V, Campo G, Silvestro A, Maristany J, Flores X, Oyarzabal L, De Miguel-Castro A, Iñiguez A, Serra A, Nombela-Franco L, Ielasi A, Tespili M, Lenzen M, Gonzalo N, Bordes P, Tebaldi M, Biscaglia S, Rodriguez-Arias JJ, Al-Shaibani S, Arevalos V, Romaguera R, Gomez-Hospital JA, Serruys PW, Sabaté M.

2021-03-0149 citations

10.1016/j.jacc.2020.12.059

Interventions

DRUGEverolimus Eluting Coronary Stent System

Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation

DEVICECobalt chromium balloon expandable stent (non-drug-eluting stent Arm)

Cobalt chromium balloon-expandable stent (non-drug-eluting stent Arm) implantation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Patients who were enrolled in the EXAMINATION trial (NCT00828087).

Exclusion criteria

* None.

Design outcomes

Primary

Measure	Time frame	Description
Patient-oriented Composite Endpoint (PoCE)	10 years	Rate of composite endpoint of all-cause death, any myocardial infarction, and any revascularization. Defined according to the Academic Research Consortium 1.

Secondary

Measure	Time frame	Description
Device-oriented Composite Endpoint (DoCE)	10 years	Rate of composite endpoint of cardiac death, Target vessel myocardial infarction, and Target lesion revascularization. Defined according to the Academic Research Consortium 1.
Rate of all cause and cardiac mortality	10 years	Defined according to the Academic Research Consortium 1.
Rate of recurrent myocardial infarction	10 years	Defined according to the Academic Research Consortium 1.
Rate of target lesion revascularization	10 years	Defined according to the Academic Research Consortium 1.
Rate of stent thrombosis	10 years	Defined according to the Academic Research Consortium 1.

Countries

Italy, Netherlands, Spain

Outcome results

None listed